Socioeconomic Value of Targeted Therapies for HER2+ Breast Cancer in National Reimbursement Drug List of China
Author(s)
Feng Yijia1, Luying Zhang, PhD2, Dennis Alexander Ostwald, PhD3, Malina Müller, BA, MA, PhD3, Wen Chen, PhD2.
1Student, Fudan University, Shanghai, China, 2Fudan University, Shanghai, China, 3WifOR institute, Darmstadt, Germany.
1Student, Fudan University, Shanghai, China, 2Fudan University, Shanghai, China, 3WifOR institute, Darmstadt, Germany.
OBJECTIVES: Breast cancer is the most prevalent cancer among women worldwide with incidence rates of 45.37/100,000, while HER2+ classification accounts for 15-25%. Targeted therapies are highly effective in HER2+ breast cancer treatment, which prolong patients’ lifetime, improve quality of life, and generate great socioeconomic benefits. However, few researches quantified the socioeconomic value of innovative medications in China.
METHODS: Socioeconomic values of 7 targeted therapies in National Reimbursement Drug list (NRDL) from 2023 to 2032 were estimated, covering Trastuzumab, Pertuzumab, Ado-trastuzumab Emtansine, pertuzumab+trastuzumab+hyaluronidase-zzxf (Subcutaneous Injection), Neratinib, Pyrotinib and Fam-trastuzumab Deruxtecan. Methodology was derived from WifOR’s annual social impact framework by firstly analyzing the added QALY of each therapy and then translating QALY into monetary values based on both paid and unpaid work. Incremental QALY of each therapy was collected from literatures by comparing with SoC in its clinical trial. Gross value added, average hours of paid and unpaid work and labor force size were acquired from China’s statistical yearbooks and official websites. Inflation rate of and discounting rate were set as 5% and 3%, respectively.
RESULTS: 7 therapies were predicted to cover a total of 1,574,471 patients over 10 years, generating 89,882 QALYs with a socioeconomic value of $4.42 billion. The therapy with the most patients covered is Trastuzumab (27.44%), followed by Pertuzumab and Trastuzumab Injection (11.68%) and Fam-trastuzumab Deruxtecan (11.37%). Pertuzumab is estimated to generate the most QALYs (31.4%), followed by Trastuzumab (25.41%) and Fam-trastuzumab Deruxtecan (14.53%). Pertuzumab, Pertuzumab and Trastuzumab Injection, Trastuzumab rank top 3 of generating most socioeconomic values, accounting for 27.30%, 26.68% and 20.6%, respectively.
CONCLUSIONS: Targeted therapies for HER2+ in breast cancer significantly improve patients’ quality of life and create great socioeconomic values. It implies that NRDL inclusion of these innovative medication not only provides reimbursement but also yields great socioeconomic impacts in China.
METHODS: Socioeconomic values of 7 targeted therapies in National Reimbursement Drug list (NRDL) from 2023 to 2032 were estimated, covering Trastuzumab, Pertuzumab, Ado-trastuzumab Emtansine, pertuzumab+trastuzumab+hyaluronidase-zzxf (Subcutaneous Injection), Neratinib, Pyrotinib and Fam-trastuzumab Deruxtecan. Methodology was derived from WifOR’s annual social impact framework by firstly analyzing the added QALY of each therapy and then translating QALY into monetary values based on both paid and unpaid work. Incremental QALY of each therapy was collected from literatures by comparing with SoC in its clinical trial. Gross value added, average hours of paid and unpaid work and labor force size were acquired from China’s statistical yearbooks and official websites. Inflation rate of and discounting rate were set as 5% and 3%, respectively.
RESULTS: 7 therapies were predicted to cover a total of 1,574,471 patients over 10 years, generating 89,882 QALYs with a socioeconomic value of $4.42 billion. The therapy with the most patients covered is Trastuzumab (27.44%), followed by Pertuzumab and Trastuzumab Injection (11.68%) and Fam-trastuzumab Deruxtecan (11.37%). Pertuzumab is estimated to generate the most QALYs (31.4%), followed by Trastuzumab (25.41%) and Fam-trastuzumab Deruxtecan (14.53%). Pertuzumab, Pertuzumab and Trastuzumab Injection, Trastuzumab rank top 3 of generating most socioeconomic values, accounting for 27.30%, 26.68% and 20.6%, respectively.
CONCLUSIONS: Targeted therapies for HER2+ in breast cancer significantly improve patients’ quality of life and create great socioeconomic values. It implies that NRDL inclusion of these innovative medication not only provides reimbursement but also yields great socioeconomic impacts in China.
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE32
Topic
Economic Evaluation
Topic Subcategory
Work & Home Productivity - Indirect Costs
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Oncology